Portfolio Expansion
Sculptor Capital LP Acquires New Stakes in Brookdale, Taiwan Semiconductor, and Several SPACs
Anonymous
Key Points
1
For Brookdale Senior Living (BKD), broker coverage included specific target/stance details: Compass Point initiated coverage with a “buy” rating and a $22.00 price target, and Stephens initiated coverage with an “overweight” rating and an $18.00 price objective (alongside Zacks downgrading from “strong-buy” to “hold”).
2
For Drugs Made In America Acquisition II (DMII), Sculptor’s stake was detailed as 500,000 shares valued at about $4.95 million, while analyst tone shifted in part via upgrades: Wall Street Zen upgraded DMII from “sell” to “hold,” and Weiss Ratings upgraded from “sell (e)” to “sell (e+),” though MarketBeat data still showed a “Sell” consensus.
3
For the Cartesian Growth Corp III (CGCT) SPAC, Sculptor’s filing showed it bought 310,165 shares (about $3.193 million) and that the position represented 0.90% ownership; the article also reported UBS Group AG increased its stake by 264.9% to 215,841 shares.
4
For Hennessy Capital Investment Corp. VII (HVII), the article cited additional buy/sell split specifics beyond an overall “hold” view: Weiss Ratings reissued “sell (d)” (June 9) while Benchmark assumed coverage with a “buy” rating; it also reported HVII opened at $10.43 and had a 1-year range of $10.12 to $10.99, alongside other large holders (e.g., Highbridge at about $15.525 million and Verbena Value at about $12.655 million).
Sculptor Capital LP disclosed a new stake in Brookdale Senior Living (BKD), buying roughly 1.2 million shares worth about $12.9 million, according to its latest 13F filing with the SEC Watchlist News. The hedge fund, led by CEO and CIO Jimmy Levin, also raised its position in Taiwan Semiconductor Manufacturing by 41.6% to 233,000 shares — a stake now worth about $70.8 million.
The moves show Sculptor betting on a mix of senior care, chipmaking, and blank-check companies known as SPACs. The filings cover positions built during the first quarter of 2026.
Sculptor Enters Brookdale Amid Split Analyst Views
Sculptor paid an implied average near $10.75 per share for its BKD stake. The $12.9 million buy comes as analysts are divided on the stock. Compass Point started coverage in January with a "buy" rating and a $22.00 price target — nearly double the implied entry price Watchlist News. Stephens followed in February with an "overweight" rating and an $18.00 target.
Not everyone is bullish. Zacks downgraded BKD from "strong-buy" to "hold" on June 15, citing valuation concerns after recent price gains. Compass Point analysts called Brookdale a "compelling demographic play" with real estate upside. The senior living sector is benefiting from the aging Baby Boomer population and a tighter supply of care facilities.
TSM Stake Grows as Sculptor Bets on AI Chips
Sculptor's Taiwan Semiconductor position jumped from about 165,000 shares to 233,000 shares — a 41.6% increase — bringing its total stake to roughly $70.8 million Watchlist News. TSM is the world's dominant chip foundry, making semiconductors for Apple, Nvidia, and most major tech companies.
TSM Chairman and CEO C.C. Wei has described the company as the "foundational enabler" for the AI era. Analysts view Sculptor's enlarged TSM position as a stabilizing anchor. It balances the firm's riskier bets elsewhere in its portfolio, giving it exposure to a high-moat business with strong long-term demand.
Sculptor Plows Into SPACs Despite Bearish Ratings
Sculptor took three new SPAC positions in Q1 2026. It bought 500,000 shares of Drugs Made In America Acquisition II (DMII) worth $4.95 million Watchlist News. It also picked up 310,165 shares of Cartesian Growth Corp III (CGCT) for about $3.19 million, giving it 0.90% ownership of that vehicle. UBS separately raised its own CGCT stake by 264.9% to 215,841 shares.
The DMII bet aligns with a policy push to bring drug manufacturing back to the United States. Wall Street Zen upgraded DMII from "sell" to "hold," and Weiss Ratings moved it from "sell (e)" to "sell (e+)." But MarketBeat's overall consensus still sits at "Sell." Sculptor appears to be making a structured bet — SPAC trust accounts give some downside protection even when ratings are poor.
Hennessy Capital Stake Highlights SPAC Arbitrage Play
Sculptor also bought 353,000 shares of Hennessy Capital Investment Corp. VII (HVII), valued at roughly $3.68 million based on an opening price of $10.43. The stock has traded in a tight range over the past year — between $10.12 and $10.99 — typical of a SPAC near its trust value. Benchmark assumed coverage with a "buy" rating, while Weiss Ratings reissued a "sell (d)" on June 9.
Sculptor is not alone in HVII. Highbridge Capital holds a stake worth about $15.5 million, and Verbena Value holds roughly $12.7 million. The cluster of sophisticated investors points to a coordinated SPAC-arbitrage approach — buying near trust value and waiting for either a deal or a redemption payout. The overall analyst consensus on HVII sits at "hold."
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
23
Articles
6
Reach
29
A
AnonymousAuthor
